Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s PN-235?

PN-235 is a synthetic peptide commercialized by Johnson & Johnson, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris).

Kezar and Everest enter lupus nephritis therapy development deal

Everest and Kezar will join forces for the Phase IIb PALIZADE trial of zetomipzomib in active lupus nephritis patients. Credit: SciePro/Shutterstock.com. Kezar Life Sciences and

September 21, 2023

Study investigates the relationship between dietary inflammatory index and stroke risk in US adults

A recent study demonstrated the potential of dietary intervention to reduce stroke incidence by half by reducing systemic inflammation.

March 25, 2024

Dana-Farber blindsided Brigham and Women’s. The blowback will be strong

This column is from Trendlines, a business newsletter that covers the forces shaping the economy in Boston and beyond. If you’d like to receive it

September 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.